Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars

Biosimilars Key For Teva As It Chases Mid-Single Digit Sales Growth

 
• By Dean Rudge

Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.

PumpkinPie
Teva is "very happy about the situation we see in the biosimilar space," according to CEO Kåre Schultz • Source: Shutterstock

More from Biosimilars

More from Products